The vast majority of India’s medical devices of which is nearly 80 per cent import-dependent, are unregulated for quality and safety. While many of these products may have regulatory certifications in other countries, the reality is that a considerable number of them are being exported from countries that do not regulate their exports. The medical devices market in India is over $15 billion (Rs 105,000 crore) and projected to grow to $50 billion by 2025 and is the fourth-largest in Asia.
Thirty years have gone by since the 1st medical device was regulated as a drug in 1989. A comprehensive regulatory framework is nearly in sight with the Draft MEDICAL DEVICES (Safety, Effectiveness & Innovation) Bill from NITI Aayog to be shortly proposed as a Separate Law.
Our policymakers in Health Ministry were surprisingly undecided and seemed to be in no urgency to usher in a ‘Patient Safety Medical Devices Law to protect patients, even after the recent ICIJ implant files or J&J incident, or the most recent ban on Transvaginal Pelvic Mesh by US Food and Drug (FDA). As Ministry of Health & Family Welfare (MoHFW) had been surprisingly very reluctant to draft a separate law preferring to attempt to amend the Drugs Act and Central Drugs Standard Control Organization (CDSCO) has a conflict of interest to empower itself the industry watchers are waiting with anxiety the details of the Draft Medical Devices Bill that NITI Aayog is reportedly working upon in consultation with other stakeholder departments and ministries to address the regulatory vacuum & the national patient safety concerns.
This story is from the Decemeber 2019 edition of Bio Spectrum.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the Decemeber 2019 edition of Bio Spectrum.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Agilent releases nextgen HPLC systems with enhanced automation and sustainability capabilities
Agilent Technologies Inc. has announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all including the biocompatible versions.
Univercells Technologies launches miniaturised scale-X Nexo Bioreactor
Univercells Technologies has announced the launch of its latest innovation, the scale-X nexo bioreactor.
Thermo Fisher and Telangana to establish Bioprocess Design Centre for novel biotherapeutics
Thermo Fisher Scientific has announced the signing of a Memorandum of Understanding (MoU) with the Government of Telangana to establish a Bioprocess Design Centre (BDC) in Genome Valley, Hyderabad.
VFL Sciences announces launch of GreatFlo Parallel Bioreactors and Fermentors
Chennai-based VFL Sciences has announced the launch of GreatFlo Parallel, a range of seamlessly parallel Bioreactors and Fermentors at the IKMC 2024 event organised by IKP Knowledge Park at Hyderabad recently, by Dr Jitendra Kumar, Managing Director, BIRAC.
Avantor opens new innovation centre for solving life science's biggest challenges
Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, has announced the opening of its new flagship Bridgewater Innovation Centre.
Waters unveils new software to deliver lab-centric business intelligence
Waters Corporation has announced the launch of waters connect Data Intelligence software, a new cloud-based application that helps customers in regulated industries improve how they access, organise, analyse, and drive productivity from laboratory information.
INST develops unique drug delivery method to improve treatment of brain TB
Researchers at the Institute of Nano Science and Technology (INST), Mohali, have created a unique way to deliver Tuberculosis (TB) medicines directly to the brain bypassing the challenging blood-brain barrier (BBB) that limits the effectiveness of many brain TB medicines.
New way to create hydrogels from viral protein fragments for improving drug delivery
Researchers from Bose Institute, an autonomous institute of the Department of Science and Technology (DST), in Kolkata, have discovered a new way to create hydrogels using tiny protein fragments of just five amino acids from the SARS-CoV-1 virus, that could help improve targeted drug delivery & reduce side effects.
Lupin appoints Claus Jepsen as President, Global Specialty
Global pharma major Lupin has announced the appointment of Claus Jepsen as President, Global Specialty.
Shyamakant Giri to join as CEO of Gland Pharma
Gland Pharma’s Board has approved the appointment of Shyamakant Giri, as the new Chief Executive Officer (CEO) of the company.